Andere talen Moberg Pharma AB

Aandelen

Vertraagde tijd Nasdaq Stockholm Andere beurzen 12:59:37 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
34,14 ^SEK	+0,41%		+14,10%	+124,61%

08/04	Moberg Pharma AB (Publ) dient een aanvraag in om een extra leverancier van terbinafine op te nemen	CI
13/02	Moberg Pharma AB (publ) rapporteert resultaten voor het vierde kwartaal eindigend op 31 december 2023	CI

Moberg Pharma : Launch update for MOB-015	23/04
Moberg Pharma : Launch update for MOB-015	23/04
Notice of Annual General Meeting in Moberg Pharma AB (publ)	12/04
Moberg Pharma Annual report for 2023	12/04
Moberg Pharma : Corporate Governance Report 2023	12/04
Moberg Pharma : Application submitted to include an additional terbinafine supplier	08/04
Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	08/04
Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	26/02
The Nomination Committee's proposal to the Annual General Meeting 2024	19/02
Moberg Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/02
Moberg Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	13/02
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication	07/02
Moberg Pharma's Interim report January - September 2023	07/11
Moberg Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Moberg Pharma strengthens the organization	07/11
Moberg Pharma Announces Leadership Changes	07/11
Moberg Pharma's Nomination Committee appointed	17-10-23
Moberg Pharma AB Appoints Nomination Committee	17-10-23
MOBERG PHARMA HAS COMPLETED ENROLLMENT TO THE PHASE 3 STUDY FOR MOB-015 IN NORTH AMERICA	09-10-23
Bulletin from Moberg Pharma's Extraordinary General Meeting	09-10-23

Geen resultaten voor deze zoekopdracht